Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

BioNexus Gene Lab (BGLC) Profit After Tax (2018 - 2025)

Historic Profit After Tax for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to -$708991.0.

  • BioNexus Gene Lab's Profit After Tax rose 4730.14% to -$708991.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.3 million, marking a year-over-year decrease of 14393.66%. This contributed to the annual value of -$1.6 million for FY2024, which is 3920.44% up from last year.
  • As of Q3 2025, BioNexus Gene Lab's Profit After Tax stood at -$708991.0, which was up 4730.14% from -$616172.0 recorded in Q2 2025.
  • In the past 5 years, BioNexus Gene Lab's Profit After Tax registered a high of $338744.0 during Q1 2021, and its lowest value of -$2.6 million during Q3 2023.
  • For the 5-year period, BioNexus Gene Lab's Profit After Tax averaged around -$304224.7, with its median value being -$103757.0 (2024).
  • Data for BioNexus Gene Lab's Profit After Tax shows a peak YoY increase of 29651.21% (in 2023) and a maximum YoY decrease of 327100.17% (in 2023) over the last 5 years.
  • Quarter analysis of 5 years shows BioNexus Gene Lab's Profit After Tax stood at $89243.0 in 2021, then tumbled by 275.89% to -$156969.0 in 2022, then skyrocketed by 296.51% to $308463.0 in 2023, then plummeted by 212.92% to -$348319.0 in 2024, then plummeted by 103.55% to -$708991.0 in 2025.
  • Its Profit After Tax was -$708991.0 in Q3 2025, compared to -$616172.0 in Q2 2025 and -$623327.0 in Q1 2025.